Eosinophil viability-enhancing activity in sputum from patients with bronchial asthma, Contributions of interleukin-5 and granulocyte/macrophage colony-stimulating factor.
To investigate the mechanisms of eosinophil activation in the airways of patients with asthma, we attempted to detect eosinophil-activating cytokines in sputum extracts obtained from asthmatic patients during acute attacks or in remission by eosinophil survival assay. Purified guinea pig eosinophils were cultured in the presence or absence of sputum extracts, and the eosinophil viability was measured on Day 4. Eosinophil viability in the presence of sputum extracts derived from patients during moderate or severe attacks was significantly higher than that for sputum obtained from patients in remission or during mild attacks or from those with other respiratory diseases, including bronchiectasis and diffuse panbronchiolitis (p < 0.05). The total symptom score during the week prior to sputum collection correlated with the eosinophil viability (rs = 0.79, p < 0.01). Eosinophil viability-enhancing activity (EVEA) in the sputum of asthmatic patients with moderate or severe attacks was neutralized by anti-IL-5 antibody and by anti-GM-CSF antibody by 19.9 +/- 13.7% and 76.9 +/- 8.2% (mean +/- SEM, n = 7), respectively. EVEA was completely neutralized by a combination of anti-IL-5 and anti-GM-CSF antibodies. There was a significant correlation between the concentration of eosinophil cationic protein (ECP) in sputum extracts and the eosinophil viability (rs = 0.54, p < 0.05). These findings suggest that IL-5 and GM-CSF are present in the sputum during asthma attacks and that these cytokines are at least partially responsible for eosinophil activation in asthma.
Adachi
T
T
Department of Respiratory Medicine, Kihara Hospital, Tokyo, Japan.
Motojima
S
S
Hirata
A
A
Fukuda
T
T
Makino
S
S
D000818:Animals; D001249:Asthma / Q000276:immunology / Q000378:metabolism*; D001798:Blood Proteins / Q000032:analysis; D002470:Cell Survival; D016207:Cytokines / Q000502:physiology; D047091:Eosinophil Granule Proteins; D004804:Eosinophils / Q000276:immunology / Q000502:physiology*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000032:analysis / Q000502:physiology*; D006168:Guinea Pigs; D006801:Humans; D015848:Interleukin-5 / Q000032:analysis / Q000502:physiology*; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D012260:Ribonucleases; D013183:Sputum / Q000737:chemistry*
D001798:Blood Proteins; D016207:Cytokines; D047091:Eosinophil Granule Proteins; D015848:Interleukin-5; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D012260:Ribonucleases